The role of immune regulatory molecules in multiple sclerosis
- 1 December 2019
- journal article
- review article
- Published by Elsevier in Journal of Neuroimmunology
- Vol. 337, 577061
Abstract
No abstract availableKeywords
This publication has 124 references indexed in Scilit:
- Tumor-infiltrating DCs suppress nucleic acid–mediated innate immune responses through interactions between the receptor TIM-3 and the alarmin HMGB1Nature Immunology, 2012
- Experimental autoimmune encephalomyelitis (EAE) as a model for multiple sclerosis (MS)British Journal of Pharmacology, 2011
- Tissue-specific expression of B7x protects from CD4 T cell–mediated autoimmunityJournal of Experimental Medicine, 2011
- VISTA, a novel mouse Ig superfamily ligand that negatively regulates T cell responsesJournal of Experimental Medicine, 2011
- T cells in multiple sclerosis and experimental autoimmune encephalomyelitisClinical and Experimental Immunology, 2010
- TIM‐3 is expressed on activated human CD4+ T cells and regulates Th1 and Th17 cytokinesEuropean Journal of Immunology, 2009
- Down‐modulation of programmed death 1 alters regulatory T cells and promotes experimental autoimmune encephalomyelitisJournal of Neuroscience Research, 2009
- PD‐1 ligands expressed on myeloid‐derived APC in the CNS regulate T‐cell responses in EAEEuropean Journal of Immunology, 2008
- Dysregulated T cell expression of TIM3 in multiple sclerosisJournal of Experimental Medicine, 2006
- BTLA is a lymphocyte inhibitory receptor with similarities to CTLA-4 and PD-1Nature Immunology, 2003